Visceral Leishmaniasis: Therapeutics and Vaccines describes current therapeutics, natural anti-leishmanial molecules, anti-leishmanial screening, and explores vaccine candidates and amastigote-based vaccination strategies for Leishmania. The book provides a precise view on VL, Leishmania parasite culture, host immunity and immunomodulation, natural compounds effective against VL, animal models for VL, and methodologies available for anti-leishmanial drug screening procedures against VL, as well as vaccine and vaccination-related information on Leishmaniasis. Readers will find concrete information on past and current hurdles facing vaccine development for Leishmania, along with scientific opportunities and the potential impact of vaccines, including problems encountered. The book is designed to increase the understanding of vaccines, particularly in VL, for students and researchers. Although vaccines are now available for many diseases, there are still challenges ahead for a vaccine for VL. The ideal vaccine must be safe and able to induce an immune response that is strong and effective. In a nutshell, a combination of chemotherapy (drugs) and immunoprophylaxis (vaccine) would be ideal to win the battle against VL.

Volume 37 will provide details on the major chemical constituents of medicinal plants and their mechanism of action as the anticancer compounds. This special issue, in addition to the previous volume (volume 36 of The Enzyme series was on Natural Products and Cancer Signaling Targets: Isoprenoids, Polyphenols and Flavonoids), will highlight the significant advance made in the field in elucidating mechanisms of anticancer effect of the major phytochemicals.

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood.

This issue of PET Clinics focuses on Total Body PET Imaging, and is edited by Drs. Lorenzo Nardo, Ramsey Badawi, Joel S. Karp and Austin Pantel. Articles will include: UC Davis update on the uEXPLORER; Zhongshan update on the uEXPLORER; UPenn update on the PennPET Explorer; Total body imaging instrumentation design considerations; 3D/4D reconstruction and quantitative total body imaging; Analysis of 4D data for total body imaging; Total body imaging and cancer; Total body imaging and metabolic disease; Total body imaging and infection; Total body imaging and musculoskeletal disease; Total body imaging and cardiovascular disease; Total body imaging and cardiac applications; Total body imaging and neuroimaging; and more!

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges.

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
There has been significant progress in the development of targeted therapy drugs that act specifically on certain cancers, and that minimize damage to normal cells. Oncologists and cancer researchers will rely on this volume to determine effective drug treatments.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only anticancer drugs, but also all other drugs that act upon related organ systems affected by cancer
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including liposome-based chemotherapy and immunotherapy, human polyomaviruses, the role of micro RNAs in CLL, and cancer and cholesterol.

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including nitric oxide-induced apoptosis in tumor cells, detection of minimal residual disease, immunity to oncogenetic human papillomavirus, and modeling prostate cancer in the mouse.

The treatment of cancer in young women and men is increasingly turning from focusing purely on survival to a recognition of the long-term effects of treatment on subsequent quality of life. In this regard, fertility is a very high priority for patients. This is the first book to explain the latest techniques in fertility preservation. Chapters cover fertility preservation in both women and men, management of cancer in pregnancy, egg donation and surrogacy, hormone replacement options, counselling and ethical issues. A multidisciplinary team of over 60 specialists were involved in this work, with contributions from leading obstetricians, medical oncologists, gynaecological oncologists, urologists and fertility specialists. The book is formally supported by the Association of Cancer Physicians (ACP). This highly patient-centred, readable text will be of value to a wide range of clinicians and physicians, and doctors in training, in their daily work.